Breakthrough Cancer Pain

Overview

Journal Curr Pain Headache Rep

Date 2014 Apr 25

PMID 24760489

Citations 12

Authors

Andrew N Davies

Affiliations

Soon will be listed here.

Abstract

Breakthrough pain is a distinct pain state that is common in patients with cancer pain and which is associated with significant morbidity in this group of patients. The aim of this article is to highlight important journal articles relating to breakthrough pain that have been published within the last year, including a systematic review of the epidemiology of breakthrough pain, the largest-ever study of the clinical features of breakthrough pain, and a network meta-analysis of the treatment of breakthrough pain.

Citing Articles

Advancing the integration of biosignal-based automated pain assessment methods into a comprehensive model for addressing cancer pain.

Cascella M, Di Gennaro P, Crispo A, Vittori A, Petrucci E, Sciorio F BMC Palliat Care. 2024; 23(1):198.

PMID: 39097739 PMC: 11297625. DOI: 10.1186/s12904-024-01526-z.

Knowledge and practice of the management of breakthrough cancer pain among general practitioners providing palliative care in Shanghai, China: a cross-sectional survey.

Yu Y, Zhang P, Chen D, Jiang S BMJ Open. 2023; 13(9):e073670.

PMID: 37770268 PMC: 10546098. DOI: 10.1136/bmjopen-2023-073670.

Effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients.

Zhou H, Wei J, Sun W, Song Z J Thorac Dis. 2023; 15(8):4314-4323.

PMID: 37691656 PMC: 10482640. DOI: 10.21037/jtd-23-375.

Management of pain in patients with bone metastases.

Jing D, Zhao Q, Zhao Y, Lu X, Feng Y, Zhao B Front Oncol. 2023; 13:1156618.

PMID: 37007073 PMC: 10063159. DOI: 10.3389/fonc.2023.1156618.

Bayesian Network Analysis for Prediction of Unplanned Hospital Readmissions of Cancer Patients with Breakthrough Cancer Pain and Complex Care Needs.

Cascella M, Racca E, Nappi A, Coluccia S, Maione S, Luongo L Healthcare (Basel). 2022; 10(10).

PMID: 36292299 PMC: 9601725. DOI: 10.3390/healthcare10101853.

References

Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W . Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage. 2013; 46(5):619-28. DOI: 10.1016/j.jpainsymman.2012.12.009. View

Portenoy R, Hagen N . Breakthrough pain: definition and management. Oncology (Williston Park). 1989; 3(8 Suppl):25-9. View

Portenoy R, Burton A, Gabrail N, Taylor D . A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain. 2010; 151(3):617-624. DOI: 10.1016/j.pain.2010.07.028. View

Rauck R, North J, Gever L, Tagarro I, Finn A . Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2009; 21(6):1308-1314. PMC: 2875549. DOI: 10.1093/annonc/mdp541. View

Kress H, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T . Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension.... Clin Ther. 2009; 31(6):1177-91. DOI: 10.1016/j.clinthera.2009.05.022. View

Portenoy R, Hagen N . Breakthrough pain: definition, prevalence and characteristics. Pain. 1990; 41(3):273-281. DOI: 10.1016/0304-3959(90)90004-W. View

Rauck R, Reynolds L, Geach J, Bull J, Stearns L, Scherlis M . Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2012; 28(5):859-70. DOI: 10.1185/03007995.2012.683111. View

Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P . A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009; 25(11):2805-15. DOI: 10.1185/03007990903336135. View

Davies A, Dickman A, Reid C, Stevens A, Zeppetella G . The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2008; 13(4):331-8. DOI: 10.1016/j.ejpain.2008.06.014. View

10.

Zeppetella G, Davies A, Eijgelshoven I, Jansen J . A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manage. 2013; 47(4):772-785.e5. DOI: 10.1016/j.jpainsymman.2013.05.020. View

11.

Portenoy R . Treatment of temporal variations in chronic cancer pain. Semin Oncol. 1997; 24(5 Suppl 16):S16-7-12. View

12.

Davies A, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, Nauck F . Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011; 15(7):756-63. DOI: 10.1016/j.ejpain.2010.12.004. View

13.

Farrar J, Cleary J, Rauck R, Busch M, Nordbrock E . Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998; 90(8):611-6. DOI: 10.1093/jnci/90.8.611. View

14.

Fallon M, Reale C, Davies A, Lux A, Kumar K, Stachowiak A . Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol. 2011; 9(6):224-31. DOI: 10.1016/j.suponc.2011.07.004. View

15.

Citron M, Kalra J, Seltzer V, Chen S, Hoffman M, Walczak M . Patient-controlled analgesia for cancer pain: a long-term study of inpatient and outpatient use. Cancer Invest. 1992; 10(5):335-41. DOI: 10.3109/07357909209024792. View

16.

Bruera E, Macmillan K, Kuehn N, Miller M . Circadian distribution of extra doses of narcotic analgesics in patients with cancer pain: a preliminary report. Pain. 1992; 49(3):311-314. DOI: 10.1016/0304-3959(92)90236-5. View

17.

Saini A, Tucci M, Tampellini M, Maina D, Bouraouia K, Giuliano P . Circadian variation of breakthrough pain in cancer patients. Eur J Pain. 2012; 17(2):264-70. DOI: 10.1002/j.1532-2149.2012.00184.x. View

18.

Fine P, Busch M . Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage. 1998; 16(3):179-83. DOI: 10.1016/s0885-3924(98)00045-1. View

19.

Portenoy R, Taylor D, Messina J, Tremmel L . A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006; 22(9):805-11. DOI: 10.1097/01.ajp.0000210932.27945.4a. View

20.

Davies A, Vriens J, Kennett A, McTaggart M . An observational study of oncology patients' utilization of breakthrough pain medication. J Pain Symptom Manage. 2008; 35(4):406-11. DOI: 10.1016/j.jpainsymman.2007.05.010. View